EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

High-dose rifampicin and clarithromycin for 4 weeks versus standard-dose rifampicin and clarithromycin for 8 weeks to treat Buruli ulcer: An open-label, individually randomized, controlled trial in Ghana

Abigail Agbanyo, Yaw Ampem Amoako iD, Charles Opondo iD, Michael Ntiamoah Oppong, Adwoa Asante-Poku, Jacob Novignon iD, Joseph Tuffour, Ishaque Saim Mintah, Ruth Dede Tuwor iD, Dzifa Kofi Ahiatrogah, Richard Adjei Akuffo, Miriam Gborglah iD und 8 weitere

PLOS Neglected Tropical Diseases · 2026

DOI: 10.1371/journal.pntd.0014783 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift PLOS Neglected Tropical Diseases, 2026. Verfasst von Abigail Agbanyo und 19 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Collaborative Research, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana. Hauptthemen laut MEDLINE: Buruli Ulcer, Rifampin, Clarithromycin, Anti-Bacterial Agents. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Institute for Health and Care Research, National Institute of Health and Care Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The current 8-week regimen of rifampicin and clarithromycin for Buruli ulcer (BU) is suboptimal. High-dose rifampicin could shorten treatment and improve outcomes. We evaluated whether a 4-week high-dose regimen could improve time to clearance of viable Mycobacterium ulcerans . Methodology In this open-label, individually randomised trial conducted in Ghana, participants with PCR-confirmed BU were assigned (1:1) to either high-dose oral rifampicin (20mg/kg) with clarithromycin (15mg/kg) for 4 weeks (HR) or standard-dose rifampicin (10mg/kg) with clarithromycin (15mg/kg) for 8 weeks (SR). All wounds were dressed with DACC-coated dressings. The primary outcome was time to clearance of viable M. ulcerans assessed by 16S rRNA qPCR up to week 20.

Findings

Between 26 th November 2021 and 31 st July 2024, 42 participants were randomised (HR:23, SR:19), which was short of the target (n = 112). The mean time to clearance was 4.9 weeks (SE 1.4) in the HR arm versus 7.0 weeks (SE 1.9) in the SR arm, with an adjusted mean difference of -0.5 weeks (95%CI -5.0 to 4.1, p = 0.835). No recurrences occurred in either arm. Paradoxical reactions were observed in 0/21 participants in the HR arm vs. 5/15 in the SR arm (adjusted OR 0.19, 95%CI 0.00-1.35, p = 0.102). Secondary infection rates were similar between groups.

Conclusion

High‑dose rifampicin combination for 4 weeks was well tolerated in this population. A nominally lower proportion of paradoxical reactions was observed in the high-dose rifampicin arm compared with standard therapy. The trial did not find evidence of significantly shorter time to microbiological clearance or healing compared with standard therapy. Larger trials are needed to determine efficacy and safety. Trial Registration Pan African Clinical Trials Repository , trial registration number: PACTR202011867644311 ( https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=14534 ).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Buruli UlcerRifampinClarithromycinAnti-Bacterial AgentsHumansGhanaFemaleMaleMycobacterium ulceransAdultTreatment OutcomeYoung AdultMiddle AgedAdolescentDrug Therapy, Combination

Substanzen

RifampinClarithromycinAnti-Bacterial Agents

Autor:innen und Institutionen

  • Centre for Collaborative Research, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana.
  • School of Medical Sciences, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana.
  • Department of Medical Statistics and the Clinical Trials Unit, Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, United Kingdom.
  • Noguchi Memorial Institute for Medical Research, University of Ghana, Accra, Ghana.
  • Centre for Social Policy Studies, University of Ghana, Accra, Ghana.
  • Department of Global Health and Development, Faculty of Public Health and Policy, London School of Hygiene and Tropical Medicine, London, United Kingdom.

ORCID-Profile: Yaw Ampem Amoako, Charles Opondo, Jacob Novignon, Ruth Dede Tuwor, Miriam Gborglah, Stephen L Walker

Förderung

  • National Institute for Health and Care Research
  • National Institute of Health and Care Research

Zitieren

APA

Agbanyo, A., Amoako, Y. A., Opondo, C., Oppong, M. N., Asante-Poku, A., Novignon, J., Tuffour, J., Mintah, I. S., Tuwor, R. D., Ahiatrogah, D. K., Akuffo, R. A., Gborglah, M., Mosweu, I., Pitt, C., Allen, E., Walker, S. L., Yeboah-Manu, D., Marks, M., Phillips, R. O., & SHARP Collaboration (2026). High-dose rifampicin and clarithromycin for 4 weeks versus standard-dose rifampicin and clarithromycin for 8 weeks to treat Buruli ulcer: An open-label, individually randomized, controlled trial in Ghana. PLOS Neglected Tropical Diseases. https://doi.org/10.1371/journal.pntd.0014783

Vancouver

Agbanyo A, Amoako YA, Opondo C, Oppong MN, Asante-Poku A, Novignon J, et al. High-dose rifampicin and clarithromycin for 4 weeks versus standard-dose rifampicin and clarithromycin for 8 weeks to treat Buruli ulcer: An open-label, individually randomized, controlled trial in Ghana. PLOS Neglected Tropical Diseases. 2026. doi:10.1371/journal.pntd.0014783

BibTeX
@article{Agbanyo2026,
  author = {Agbanyo, Abigail and Amoako, Yaw Ampem and Opondo, Charles and Oppong, Michael Ntiamoah and Asante-Poku, Adwoa and Novignon, Jacob and Tuffour, Joseph and Mintah, Ishaque Saim and Tuwor, Ruth Dede and Ahiatrogah, Dzifa Kofi and Akuffo, Richard Adjei and Gborglah, Miriam and Mosweu, Iris and Pitt, Catherine and Allen, Elizabeth and Walker, Stephen L and Yeboah-Manu, Dorothy and Marks, Michael and Phillips, Richard Odame and SHARP Collaboration, SHARP Collaboration},
  title = {High-dose rifampicin and clarithromycin for 4 weeks versus standard-dose rifampicin and clarithromycin for 8 weeks to treat Buruli ulcer: An open-label, individually randomized, controlled trial in Ghana},
  journal = {PLOS Neglected Tropical Diseases},
  year = {2026},
  doi = {10.1371/journal.pntd.0014783}
}
Kostenlos starten →